Search Results
Aug 12, 2026, 16:05 ET Hongli Group Inc. Announces Compliance with Nasdaq Minimum Bid Price Requirement
WEIFANG, China, Aug. 12, 2026 /PRNewswire/ -- Hongli Group Inc. (the "Company") (Nasdaq: HLP), a cold roll formed steel profile manufacturer, today announced that on August 7, 2026, it received a notification letter from Nasdaq Listing Qualifications
More news about: Hongli Group Inc.
Aug 10, 2026, 10:31 ET Major Depressive Disorder Market is Predicted to Grow During the Forecast Period (2026-2036) as Novel Antidepressants are Expected to Enter the Market | DelveInsight
coming years. The promising major depressive disorder therapies in clinical trials include Seltorexant, Azetukalner, Itruvone (PH10), HLP003, Osavampator, Brenipatide, Bretisilocin, Icalcaprant (ABBV-1354), Elunetirom (ABX-002), DT120, Zelquistinel, Forvisirvat (SP-624), ALTO-300, GlyphAllo
More news about: DelveInsight Business Research, LLP
Jul 21, 2026, 10:54 ET Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
regulatory authorities have not evaluated claims regarding NSAs or HLP003, HLP004 and other programs of the Company. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of NSAs, HLP003, HLP004 or other programs of the Company can diagnose, treat, cure
More news about: Helus Pharma
Jul 21, 2026, 09:00 ET A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening
Results.Statements regarding HLP003 and the APPROACH, EMBRACE, and EXTEND studies refer to an investigational drug candidate that has not been approved by the FDA or any other regulatory authority. Breakthrough Therapy Designation does not constitute approval and does not guarantee that HLP003 will ever be approved
More news about: USA News Group
Jul 21, 2026, 08:30 ET Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates
dataAPPROACH topline data readout on track for Q4 2026HLP003 previously granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration ("FDA")HLP003 Phase 2 data demonstrated durable efficacy, with a mean ~23-point reduction in Montgomery-Asberg
More news about: Market News Updates
Jul 17, 2026, 08:50 ET Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
next HLP004 study by the end of Q3 2026.Helus also has money in the bank against its readout. On June 25, 2026, it closed a US$50 million underwritten offering, selling 10,309,280 shares at US$4.85 through a syndicate led by Cantor and Barclays, with proceeds earmarked for HLP003, HLP004, the preclinical
More news about: USA News Group
Jul 09, 2026, 17:00 ET Hongli Group Inc. Receives Nasdaq Notice Regarding Minimum Bid Price Deficiency
WEIFANG, China, July 9, 2026 /PRNewswire/ -- Hongli Group Inc. (the "Company") (Nasdaq: HLP), a cold roll formed steel profile manufacturer, today announced that on July 2, 2026, it received a deficiency letter (the "Notice") from the Nasdaq
More news about: Hongli Group Inc.
Jul 07, 2026, 08:30 ET Hongli Group Inc. Provides Update on Proposed Strategic Collaboration with Sidus Energy Storage
marketsWEIFANG, China, July 7, 2026 /PRNewswire/ -- Hongli Group Inc. (Nasdaq: HLP) ("Hongli Group" or the "Company"), a cold roll formed steel profile manufacturer, today provided an update regarding the advanced battery technology
More news about: HONGLI GROUP INC.
Jun 26, 2026, 09:30 ET A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
antidepressants. HLP003 is the lead candidate, now in Phase 3 for the adjunctive treatment of MDD; the Company is also developing HLP004, an NSA in Phase 2 for generalized anxiety disorder, alongside a broader portfolio of investigational NSAs.The FDA's Breakthrough Therapy Designation, which HLP003 has
More news about: USA News Group
Jun 15, 2026, 11:38 ET Hongli Group Inc. Entered into Strategic Non-Binding MOU with Sidus Energy Storage, Inc. to Explore Potential Advanced Battery Manufacturing Collaboration
SolutionsWEIFANG, China, June 15, 2026 /PRNewswire/ -- Hongli Group Inc. (Nasdaq: HLP) (the "Company" or "Hongli Group"), a cold roll formed steel profile manufacturer, today announced that it has entered into a non-binding Memorandum
More news about: Hongli Group Inc.
Jun 04, 2026, 10:01 ET Generalized Anxiety Disorder Market Forecast Shows Strong CAGR During the Forecast Period (2026-2036) Driven by Innovative Therapies | DelveInsight
growing investments in innovative therapies such as DT120 ODT (LSD D-Tartrate) (Definium Therapeutics), Ulotaront (SEP-363856) (Sumitomo Pharma/Otsuka), HLP004 (Helus Pharma), ITI-1284 (Intra-Cellular Therapies, Inc.), ABBV-932 (AbbVie), and others, and supportive regulatory frameworks, reports DelveInsight.
More news about: DelveInsight Business Research, LLP
Jun 03, 2026, 08:30 ET Hongli Group Inc. Updates Its Business Strategy, Focusing on Solid-State Lithium Batteries
WEIFANG, China, June 3, 2026 /PRNewswire/ -- Hongli Group Inc. (Nasdaq: HLP) (the "Company" or "Hongli Group"), a cold roll formed steel profile manufacturer, today announced a strategic update following its previously announced
More news about: Hongli Group Inc.
May 28, 2026, 08:30 ET Hongli Group Inc. Engages Battery Technology Expert Dr. Phillip A. Medina IV as Independent Technical Advisor for Energy Storage Initiatives
WEIFANG, China, May 28, 2026 /PRNewswire/ -- Hongli Group Inc. (Nasdaq: HLP) (the "Company" or "Hongli Group"), a cold roll formed steel profile manufacturer, today announced that it has engaged Dr. Phillip A. Medina IV as an
More news about: Hongli Group Inc.
May 19, 2026, 09:00 ET Hongli Group Inc. Plans to Establish New Energy Solid-State Battery Division to Explore Opportunities in Advanced Materials and Energy Storage
technologiesWEIFANG, China, May 19, 2026 /PRNewswire/ -- Hongli Group Inc. (Nasdaq: HLP) (the "Company" or "Hongli Group"), a cold roll formed steel profile manufacturer, today announced that it plans to establish a New Energy Solid-State
More news about: Hongli Group Inc.
May 13, 2026, 08:25 ET Hongli Group Inc. Reports Robust Fiscal Year 2025 Results: Revenue Grows 39% to $19.6 Million as Company Delivers $3.8 Million Profit Turnaround
WEIFANG, China, May 13, 2026 /PRNewswire/ -- Hongli Group Inc. (Nasdaq: HLP) (the "Company" or "Hongli Group"), a cold roll formed steel profile manufacturer, today announced its financial results for the fiscal year ended December
More news about: Hongli Group Inc.
May 05, 2026, 09:00 ET Hongli Group Inc. Announces Strategic Plan to Explore Opportunities in Clean Energy and Energy Storage Applications
WEIFANG, China, May 5, 2026 /PRNewswire/ -- Hongli Group Inc. (Nasdaq: HLP) (the "Company" or "Hongli Group"), a cold roll formed steel profile manufacturer, today announced its strategic decision to explore opportunities in
More news about: Hongli Group Inc.
Apr 07, 2026, 10:00 ET 24PET BY PETPLACE LAUNCHES 24PETSHELTER INTRODUCING A MORE POWERFUL WAY TO SUPPORT SHELTERS
pets and the people who care for them.PetPlace Holdings, LLC, and its subsidiaries, Pethealth Services (USA) LLC, Pethealth Services Inc., and HLP, Inc., are owned by Independence Pet Holdings, Inc. (IPH), an organization that manages a diverse and broad portfolio of modern pet health brands offering
More news about: 24Pet
Mar 31, 2026, 09:00 ET Independence Pet Holdings Promotes Michael Landsberger as New General Manager of PetPlace
for all, and every pet thrives in a loving home. PetPlace Holdings, LLC, and its subsidiaries, Pethealth Services (USA) LLC, Pethealth Services Inc., HLP, Inc., and PetPlace Insurance Agency, LLC, are owned by Independence Pet Holdings, Inc. (IPH), an organization that manages a diverse and broad portfolio
More news about: Independence Pet Holdings, Inc.
Mar 09, 2026, 10:50 ET CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions
Michael Cola, CEO of Helus Pharma. "We are encouraged by these data and the potential for HLP004 to bring hope to GAD patients.""These Phase 2 results support the continued development of HLP004, and I am encouraged by the magnitude of improvement observed over standard of care treatments,
More news about: USA News Group
Mar 05, 2026, 09:30 ET Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion
encouraged by these data and the potential for HLP004 to bring hope to GAD patients. The Company's broad intellectual property portfolio has been leveraged once again to create what we feel are best in class products and we are further excited to release the data on HLP003 targeted at major depressive disorder
More news about: Market News Updates
Feb 27, 2026, 11:44 ET Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments
our conviction that our novel serotonergic agonist molecules, such as HLP004, can potentially deliver meaningful outcomes with greater consistency and commercial feasibility," said Michael Cola, CEO of Helus Pharma.HLP004, a proprietary intramuscular compound informed by the SPL026 clinical
More news about: Equity Insider
Feb 26, 2026, 12:07 ET Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders
our conviction that our novel serotonergic agonist molecules, such as HLP004, can potentially deliver meaningful outcomes with greater consistency and commercial feasibility," said Michael Cola, CEO of Helus Pharma.HLP004, a proprietary intramuscular compound informed by the SPL026 clinical
More news about: USA News Group
Feb 10, 2026, 08:30 ET Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market
programsAppointed as Helus Pharma advances its pipeline toward key clinical milestones, including expected Phase 2 data for HLP004 this quarter and Phase 3 topline data for HLP003 later this yearThis news release constitutes a "designated news release" for the purpose of the Company's
More news about: Market News Updates
Dec 11, 2025, 10:00 ET 24Petwatch Microchip Registry to Transition to PetPlace.com in 2026
for all, and every pet thrives in a loving home. PetPlace Holdings, LLC, and its subsidiaries, Pethealth Services (USA) LLC, Pethealth Services Inc., HLP, Inc., and PetPlace Insurance Agency, LLC, are owned by Independence Pet Holdings, Inc. (IPH), an organization that manages a diverse and broad portfolio
More news about: PetPlace.com
Sep 24, 2025, 16:34 ET Hatcher Landscape Partners (HLP) Acquires GreenView Partners, Sowing Seeds for Future Growth
communities." About Hatcher Landscape PartnersHatcher Landscape Partners (HLP) strives to be the premier commercial landscape services provider in the Southeastern United States. HLP unites respected, mission-driven team members under a steadfast commitment to shared
More news about: Michael Hatcher & Associates